Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Breast Neoplasms 9 Carcinoma, Non-Small-Cell Lung 6 Carcinoma, Hepatocellular 6 Recurrence 5 Pancreatic Neoplasms 5 Neoplasms 5 Stomach Neoplasms 4 Solid Tumor 4 Melanoma 4 Liver Neoplasms 4 Advanced Solid Tumors 4 Neoplasm Metastasis 3 Nasopharyngeal Carcinoma 3 Leukemia, Myeloid, Acute 3 Biliary Tract Neoplasms 3 Advanced Solid Tumor 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Thoracic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Lung Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Esophageal Neoplasms 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Urinary Bladder Neoplasms 1 Squamous Cell Lung Cancer 1

Interventions

Thyrotropin Alfa 2 apatinib 1 anlotinib 1 Sorafenib 1 Iodine-131 1 Injections 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Differentiated Thyroid Cancer × Injections × Clear all

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡